Literature DB >> 16261404

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.

Steven J Van Laere1, Gert G Van den Eynden, Ilse Van der Auwera, Melanie Vandenberghe, Peter van Dam, Eric A Van Marck, Kenneth L van Golen, Peter B Vermeulen, Luc Y Dirix.   

Abstract

Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer with high metastatic potential. Most patients have lymph node involvement at the time of diagnosis and 1/3 of the patients have distant metastases. In a previous study, we demonstrated that IBC is a distinct form of breast cancer in comparison with non-IBC. The aim of this study was to investigate the presence of the different molecular subtypes in our data set of 16 IBC and 18 non-IBC specimen. Therefore, we selected an 'intrinsic gene set' of 144 genes, present on our cDNA chips and common to the 'intrinsic gene set' described by Sorlie et al. [PNAS, 2003]. This set of genes was tested for performance in the Norway/Stanford data set by unsupervised hierarchical clustering. Expression centroids were then calculated for the core members of each of the five subclasses in the Norway/Stanford data set and used to classify our own specimens by calculating Spearman correlations between each sample and each centroid. We identified the same cell-of-origin subtypes in IBC as those already described in non-IBC. The classification was in good agreement with immunohistochemical data for estrogen receptor protein expression and cytokeratin 5/6 protein expression. Confirmation was done by an alternative unsupervised hierarchical clustering method. The robustness of this classification was assessed by an unsupervised hierarchical clustering with an alternative gene set of 141 genes related to the cell-of-origin subtypes, selected using a discriminating score and iterative random permutation testing. The contribution of the different cell-of-origin subtypes to the IBC phenotype was investigated by principal component analysis. Generally, the combined ErbB2-overexpressing and basal-like cluster was more expressed in IBC compared to non-IBC, whereas the combined luminal A, luminal B and normal-like cluster was more pronounced in non-IBC compared to IBC. The presence of the same molecular cell-of-origin subtypes in IBC as in non-IBC does not exclude the specific molecular nature of IBC, since gene lists that characterize IBC and non-IBC are entirely different from gene lists that define the different cell-of-origin subtypes, as evidenced by principal component analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261404     DOI: 10.1007/s10549-005-9015-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  36 in total

1.  Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

Authors:  Maria J Sambade; Randall J Kimple; J Terese Camp; Eldon Peters; Chad A Livasy; Carolyn I Sartor; Janiel M Shields
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

2.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

3.  Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.

Authors:  Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Tse K Yu; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Melissa L Bondy; Wei Yang; Jie S Willey; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz
Journal:  Oncologist       Date:  2011-12-06

Review 4.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

5.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

6.  Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines.

Authors:  Rebecca L Hillyer; Padma Sirinvasin; Madhura Joglekar; Robert A Sikes; Kenneth L van Golen; Anja Nohe
Journal:  Clin Exp Metastasis       Date:  2012-05-20       Impact factor: 5.150

7.  Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.

Authors:  Amanda Valeta-Magara; Abhilash Gadi; Viviana Volta; Beth Walters; Rezina Arju; Shah Giashuddin; Hua Zhong; Robert J Schneider
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

8.  How do I treat inflammatory breast cancer?

Authors:  Della Makower; Joseph A Sparano
Journal:  Curr Treat Options Oncol       Date:  2013-03

9.  Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.

Authors:  Madhuri Kakarala; Laura Rozek; Michele Cote; Samadhi Liyanage; Dean E Brenner
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

10.  Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Authors:  Mona M Mohamed; Eslam A El-Ghonaimy; Mohamed A Nouh; Robert J Schneider; Bonnie F Sloane; Mohamed El-Shinawi
Journal:  Int J Biochem Cell Biol       Date:  2013-11-26       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.